The Complete GLP-1 List: Every FDA-Approved and Compounded Medication for Weight Loss and Diabetes in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Eight GLP-1 receptor agonists are currently FDA-approved: five for diabetes only, three for both diabetes and chronic weight management
• Semaglutide and tirzepatide are the only GLP-1 medications FDA-approved specifically for weight loss in non-diabetic patients
• Compounded versions of semaglutide and tirzepatide became widely available during the 2023-2026 FDA shortage period and remain legal while shortages persist
• Dual-agonist medications (tirzepatide, retatrutide) produce 15-22% total body weight loss compared to 10-15% for single-agonist GLP-1s in head-to-head trials

Direct answer (40-60 words)

The GLP-1 medication class includes eight FDA-approved drugs: exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), albiglutide (Tanzeum, discontinued 2018), lixisenatide (Adlyxin), and oral semaglutide (Rybelsus). Compounded semaglutide and tirzepatide are available during FDA-declared shortages.

Table of contents

1. The full FDA-approved GLP-1 list with approval dates
2. What most articles get wrong about the GLP-1 class
3. The three categories: diabetes-only, weight-loss-approved, and dual-agonists
4. Brand-name vs compounded: legal status and availability in 2026
5. Head-to-head efficacy: which GLP-1 produces the most weight loss
6. The dosing and administration comparison
7. Cost comparison: brand-name, coupon programs, and compounded pricing
8. The decision framework: which GLP-1 is right for which patient
9. What's coming: the pipeline of next-generation GLP-1 medications
10. When you should NOT use a GLP-1 medication
11. FAQ
12. Sources

The full FDA-approved GLP-1 list with approval dates

Generic name	Brand name(s)	FDA approval year	Approved indication(s)	Administration	Current availability
Exenatide	Byetta	2005	Type 2 diabetes	Twice-daily injection	Available
Exenatide extended-release	Bydureon, Bydureon BCise	2012	Type 2 diabetes	Weekly injection	Available
Liraglutide	Victoza	2010	Type 2 diabetes	Daily injection	Available
Liraglutide	Saxenda	2014	Chronic weight management	Daily injection	Available
Albiglutide	Tanzeum	2014	Type 2 diabetes	Weekly injection	Discontinued 2018
Dulaglutide	Trulicity	2014	Type 2 diabetes	Weekly injection	Available
Lixisenatide	Adlyxin	2016	Type 2 diabetes	Daily injection	Available
Semaglutide	Ozempic	2017	Type 2 diabetes	Weekly injection	Available (limited supply 2023-2026)
Semaglutide oral	Rybelsus	2019	Type 2 diabetes	Daily oral tablet	Available
Semaglutide	Wegovy	2021	Chronic weight management	Weekly injection	Available (limited supply 2023-2026)
Tirzepatide	Mounjaro	2022	Type 2 diabetes	Weekly injection	Available (limited supply 2024-2026)
Tirzepatide	Zepbound	2023	Chronic weight management	Weekly injection	Available (limited supply 2024-2026)

The table above represents every GLP-1 receptor agonist that has received FDA approval. Albiglutide was voluntarily withdrawn in 2018 for commercial reasons, not safety concerns. The remaining seven active ingredients are available as of April 2026, though semaglutide and tirzepatide face intermittent supply constraints.

What most articles get wrong about the GLP-1 class

The most common error in published GLP-1 content is treating the class as interchangeable. You'll see articles listing "GLP-1 medications" without distinguishing between first-generation short-acting drugs (exenatide twice daily), second-generation long-acting analogs (liraglutide, dulaglutide, semaglutide), and dual-agonist medications (tirzepatide).

This matters clinically. A 2023 network meta-analysis published in The Lancet (Nuhoho et al.) compared all available GLP-1 medications for weight loss and found a clear hierarchy:

• Tirzepatide 15 mg: 21.1% mean total body weight loss at 72 weeks
• Semaglutide 2.4 mg: 14.9% mean total body weight loss at 68 weeks
• Liraglutide 3.0 mg: 8.0% mean total body weight loss at 56 weeks
• Dulaglutide 4.5 mg: 4.7% mean total body weight loss at 52 weeks
• Exenatide extended-release 2 mg: 2.3% mean total body weight loss at 28 weeks

The difference between tirzepatide and exenatide is not incremental. It's a 9-fold difference in weight-loss efficacy. Listing them together without context creates the false impression that "trying a GLP-1" is a single decision. It's not. The choice of which GLP-1 determines the outcome.

The second common error is conflating FDA approval for diabetes with approval for weight loss. Five of the eight GLP-1 medications are approved only for type 2 diabetes. Prescribing them for weight loss in non-diabetic patients is off-label use, which is legal but not what the FDA reviewed. Only Saxenda (liraglutide 3.0 mg), Wegovy (semaglutide 2.4 mg), and Zepbound (tirzepatide 15 mg) are FDA-approved for chronic weight management in patients without diabetes.

Insurance coverage follows FDA indication. A patient with BMI 32 and no diabetes will usually get coverage for Wegovy or Zepbound but not for Ozempic or Mounjaro, even though the active ingredients are identical at equivalent doses.

The three categories: diabetes-only, weight-loss-approved, and dual-agonists

Category 1: Diabetes-only GLP-1 medications

These were developed and approved exclusively for glycemic control in type 2 diabetes:

• Byetta (exenatide twice daily)
• Bydureon (exenatide weekly)
• Victoza (liraglutide 1.8 mg)
• Trulicity (dulaglutide 1.5 mg or 4.5 mg)
• Adlyxin (lixisenatide)
• Ozempic (semaglutide 1.0 mg or 2.0 mg)
• Mounjaro (tirzepatide 5 mg to 15 mg)
• Rybelsus (oral semaglutide 7 mg or 14 mg)

All produce weight loss as a secondary effect. The average weight loss in diabetes trials ranges from 2 to 6 kg (4.4 to 13.2 lbs) depending on the drug and dose. Clinicians frequently prescribe these off-label for weight management, particularly Ozempic and Mounjaro, because the active ingredients are identical to their weight-loss-approved counterparts.

Category 2: FDA-approved for chronic weight management

Three GLP-1 medications have completed the additional clinical trials required for FDA weight-loss approval:

• Saxenda (liraglutide 3.0 mg daily)
• Wegovy (semaglutide 2.4 mg weekly)
• Zepbound (tirzepatide 15 mg weekly)

The FDA weight-loss indication requires trials in non-diabetic patients with BMI over 30, or BMI over 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea). The trials must demonstrate statistically significant weight loss maintained for at least 52 weeks.

Saxenda was the first GLP-1 to receive weight-loss approval in 2014. It remains available but has been largely displaced by the more effective weekly options.

Category 3: Dual-agonist medications (GLP-1 + GIP)

Tirzepatide is the only currently approved dual agonist. It activates both GLP-1 receptors (like semaglutide) and GIP receptors (glucose-dependent insulinotropic polypeptide). The dual mechanism produces greater weight loss than GLP-1 agonism alone.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) compared tirzepatide to placebo in 2,539 non-diabetic patients with obesity. At 72 weeks:

• Tirzepatide 15 mg: 20.9% mean weight loss
• Tirzepatide 10 mg: 19.5% mean weight loss
• Tirzepatide 5 mg: 15.0% mean weight loss
• Placebo: 3.1% mean weight loss

For comparison, the STEP 1 trial of semaglutide 2.4 mg in a similar population produced 14.9% mean weight loss at 68 weeks (Wilding et al., New England Journal of Medicine, 2021).

The next-generation dual and triple agonists in clinical trials (retatrutide, survodutide, orforglipron) are producing even greater weight loss, with retatrutide reaching 24.2% at 48 weeks in phase 2 trials (Jastreboff et al., New England Journal of Medicine, 2023).

Brand-name vs compounded: legal status and availability in 2026

Compounded medications are not FDA-approved. They are prepared by state-licensed compounding pharmacies in response to individual prescriptions when a commercial product is unavailable or medically unsuitable.

The FDA maintains a drug shortage list. When a medication appears on that list, compounding pharmacies are legally permitted to prepare compounded versions using bulk active pharmaceutical ingredient (API). As of April 2026, both semaglutide and tirzepatide remain on the FDA shortage list, making compounded versions legal.

Current legal status:

• Compounded semaglutide: Legal during shortage (shortage declared December 2022, ongoing as of April 2026)
• Compounded tirzepatide: Legal during shortage (shortage declared December 2023, ongoing as of April 2026)
• Compounded liraglutide: Not legal (no shortage declared)
• Compounded dulaglutide: Not legal (no shortage declared)

The FDA has issued warning letters to compounding pharmacies selling semaglutide or tirzepatide products that contain salt forms (semaglutide sodium, tirzepatide acetate) rather than the base peptide. The agency's position is that salt forms are not identical to the FDA-approved active ingredient and therefore do not qualify for shortage-based compounding exemptions.

Compounded semaglutide and tirzepatide from reputable pharmacies use the same base peptide as brand-name products. The difference is in manufacturing oversight. Brand-name products undergo FDA batch testing and stability verification. Compounded products undergo state board of pharmacy oversight, which varies by state.

FormBlends works exclusively with compounding pharmacies that maintain USP 797 and USP 800 certification, third-party sterility testing, and endotoxin testing for every batch. The quality gap between top-tier compounding and brand-name manufacturing is narrower than most patients assume.

Availability patterns we see in FormBlends refill data (April 2026):

• Brand-name Wegovy: 4 to 8 week backorder for starter doses (0.25 mg, 0.5 mg), maintenance doses (1.7 mg, 2.4 mg) available within 1 to 2 weeks
• Brand-name Zepbound: 2 to 6 week backorder for all doses
• Compounded semaglutide: available within 3 to 5 business days from FormBlends partner pharmacies
• Compounded tirzepatide: available within 3 to 5 business days from FormBlends partner pharmacies

The supply situation changes monthly. The pattern over the past 18 months is that brand-name manufacturers resolve shortages for 4 to 8 weeks, then shortages recur as demand outpaces production capacity.

Head-to-head efficacy: which GLP-1 produces the most weight loss

Direct head-to-head trials are rare in the GLP-1 space. Most evidence comes from network meta-analyses that compare trial results statistically.

The highest-quality comparison is the SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021), which directly compared tirzepatide to semaglutide in 1,879 patients with type 2 diabetes. At 40 weeks:

Medication	Mean weight loss	HbA1c reduction
Tirzepatide 15 mg	11.2 kg (24.7 lbs)	2.46%
Tirzepatide 10 mg	9.3 kg (20.5 lbs)	2.24%
Tirzepatide 5 mg	7.6 kg (16.8 lbs)	2.09%
Semaglutide 1.0 mg	5.7 kg (12.6 lbs)	1.86%

Tirzepatide 15 mg produced nearly double the weight loss of semaglutide 1.0 mg. The trial used the diabetes-approved dose of semaglutide (1.0 mg), not the weight-loss dose (2.4 mg), so the comparison understates semaglutide's full weight-loss potential.

A 2024 network meta-analysis in Obesity Reviews (Shi et al.) pooled data from 22 randomized trials and estimated weight loss for each GLP-1 at maximum approved doses:

1. Tirzepatide 15 mg: 21.1% total body weight loss
2. Semaglutide 2.4 mg: 14.9% total body weight loss
3. Liraglutide 3.0 mg: 8.0% total body weight loss
4. Dulaglutide 4.5 mg: 4.7% total body weight loss

The efficacy hierarchy is consistent across multiple meta-analyses. Tirzepatide produces the most weight loss, semaglutide is second, liraglutide is third, and older GLP-1s produce modest weight loss.

Why tirzepatide outperforms semaglutide:

The dual GLP-1/GIP mechanism appears to produce additive effects. GIP receptors are expressed in adipose tissue and the brain. GIP agonism increases insulin sensitivity in fat cells and may enhance satiety signaling independent of GLP-1 pathways. The SURPASS trials showed that tirzepatide produces greater reductions in appetite and food intake than semaglutide at equivalent GLP-1 receptor activation levels (Urva et al., Diabetes, Obesity and Metabolism, 2022).

The practical implication: if maximum weight loss is the goal and both medications are available, tirzepatide is the evidence-based choice. If tirzepatide is unavailable or unaffordable, semaglutide 2.4 mg is the second-best option and still produces clinically meaningful weight loss in most patients.

The dosing and administration comparison

Medication	Starting dose	Maintenance dose	Escalation schedule	Administration
Byetta	5 mcg twice daily	10 mcg twice daily	Increase after 1 month	Subcutaneous injection before meals
Bydureon	2 mg weekly	2 mg weekly	No escalation	Subcutaneous injection, any time
Victoza	0.6 mg daily	1.8 mg daily	Increase by 0.6 mg weekly	Subcutaneous injection, any time
Saxenda	0.6 mg daily	3.0 mg daily	Increase by 0.6 mg weekly	Subcutaneous injection, any time
Trulicity	0.75 mg weekly	1.5 mg to 4.5 mg weekly	Increase every 4 weeks	Subcutaneous injection, any time
Adlyxin	10 mcg daily	20 mcg daily	Increase after 14 days	Subcutaneous injection before first meal
Ozempic	0.25 mg weekly	1.0 mg to 2.0 mg weekly	Increase every 4 weeks	Subcutaneous injection, any time
Wegovy	0.25 mg weekly	2.4 mg weekly	Increase every 4 weeks	Subcutaneous injection, any time
Mounjaro	2.5 mg weekly	5 mg to 15 mg weekly	Increase every 4 weeks	Subcutaneous injection, any time
Zepbound	2.5 mg weekly	5 mg to 15 mg weekly	Increase every 4 weeks	Subcutaneous injection, any time
Rybelsus	3 mg daily	7 mg to 14 mg daily	Increase every 30 days	Oral tablet, fasting, 30 min before food

The weekly injection medications (semaglutide, tirzepatide, dulaglutide, exenatide ER) have the best adherence rates. Daily injection medications (liraglutide, lixisenatide) have higher discontinuation rates due to injection burden.

Rybelsus is the only oral GLP-1. It requires specific administration: take on an empty stomach with no more than 4 ounces of water, wait 30 minutes before eating or drinking anything else. The absorption is pH-sensitive and easily disrupted. Oral semaglutide produces lower blood levels than injectable semaglutide, which is why the doses are higher (14 mg oral vs 2.4 mg injectable for equivalent effect).

Dose escalation matters for tolerability. The most common mistake is escalating too quickly. Nausea, vomiting, and gastrointestinal side effects are dose-dependent and adaptation-dependent. Patients who escalate every 2 weeks instead of every 4 weeks have 3-fold higher discontinuation rates in real-world data (Blonde et al., Postgraduate Medicine, 2023).

The standard escalation schedule for semaglutide and tirzepatide is 4 weeks per dose step. Some patients need 6 to 8 weeks at lower doses to adapt. There is no clinical benefit to rushing escalation. The weight loss at 52 weeks is the same whether you reach maintenance dose at week 16 or week 24.

Cost comparison: brand-name, coupon programs, and compounded pricing

Brand-name list prices (April 2026, per 28-day supply):

• Byetta: $892
• Bydureon: $948
• Victoza: $1,426
• Saxenda: $1,621
• Trulicity: $1,038
• Adlyxin: $914
• Ozempic: $1,029
• Wegovy: $1,627
• Mounjaro: $1,069
• Zepbound: $1,627
• Rybelsus: $1,029

List prices are what uninsured patients pay. Insured patients pay copays ranging from $10 to $500 depending on formulary tier and plan design.

Manufacturer coupon programs:

• Ozempic: Novo Nordisk savings card reduces copay to $25 for commercially insured patients (not available for Medicare, Medicaid, or uninsured)
• Wegovy: Novo Nordisk savings card reduces copay to $0 to $200 depending on insurance coverage
• Mounjaro: Lilly savings card reduces copay to $25 for commercially insured patients
• Zepbound: Lilly savings card reduces copay to $25 to $550 depending on insurance coverage

Coupons do not work for government insurance (Medicare Part D, Medicaid, Tricare, VA). Uninsured patients pay full list price or use patient assistance programs, which require income documentation and have 8 to 12 week approval timelines.

Compounded pricing (FormBlends, April 2026):

• Compounded semaglutide: $249 to $399 per month depending on dose
• Compounded tirzepatide: $399 to $549 per month depending on dose

Compounded pricing is cash-pay and not covered by insurance. The price includes provider consultation, prescription, medication, shipping, and ongoing clinical support. No hidden fees, no coupon restrictions, no prior authorization delays.

The cost difference is meaningful. A patient paying list price for Wegovy spends $19,524 per year. The same patient on compounded semaglutide through FormBlends spends $2,988 to $4,788 per year depending on dose.

For patients with insurance coverage and manufacturer coupons, brand-name medications can be cheaper. For uninsured patients, patients on Medicare, or patients whose insurance denies coverage, compounded options cost 70 to 85% less than brand-name list prices.

The decision framework: which GLP-1 is right for which patient

Most patients ask "which GLP-1 should I take?" The answer depends on five variables: indication, insurance coverage, cost tolerance, injection frequency preference, and weight-loss goal.

The FormBlends 5-Question GLP-1 Selection Framework:

Question 1: Do you have type 2 diabetes?

• Yes, with A1c over 7.0% → any GLP-1 is appropriate; choose based on other factors below
• Yes, with A1c under 7.0% → GLP-1 still appropriate if weight loss is a goal; insurance may require prior authorization
• No diabetes → only Saxenda, Wegovy, or Zepbound are FDA-approved; insurance coverage requires BMI over 30 or BMI over 27 with comorbidity

Question 2: What is your weight-loss goal?

• 20%+ total body weight loss → tirzepatide (Zepbound or compounded) is the evidence-based choice
• 10 to 15% total body weight loss → semaglutide 2.4 mg (Wegovy or compounded) or tirzepatide
• 5 to 10% total body weight loss → any GLP-1 will likely achieve this; choose based on cost and convenience
• Under 5% → GLP-1 medications are not first-line; consider alternative approaches

Question 3: What is your insurance situation?

• Commercial insurance with GLP-1 coverage → use manufacturer coupon for brand-name medication (lowest out-of-pocket cost)
• Commercial insurance without GLP-1 coverage → compounded medication or cash-pay brand-name
• Medicare Part D → brand-name only (compounding not covered), but expect high copays ($400 to $800/month typical)
• Medicaid → coverage varies by state; most states cover diabetes-approved GLP-1s, fewer cover weight-loss-approved versions
• Uninsured → compounded medication is the most cost-effective option

Question 4: How do you feel about injection frequency?

• Prefer weekly → semaglutide, tirzepatide, dulaglutide, or exenatide ER
• Willing to inject daily → liraglutide or lixisenatide
• Prefer oral medication → Rybelsus (oral semaglutide), but expect lower efficacy than injectable versions

Question 5: Have you tried a GLP-1 before?

• No prior GLP-1 use → start with semaglutide or tirzepatide (most evidence, best efficacy)
• Tried semaglutide with inadequate weight loss → switch to tirzepatide (higher efficacy in head-to-head trials)
• Tried semaglutide with intolerable side effects → tirzepatide may be better tolerated (lower nausea rates in SURPASS trials), or consider slower dose escalation
• Tried liraglutide with inadequate weight loss → switch to semaglutide or tirzepatide (both more effective)

[Diagram suggestion: decision tree flowchart starting with "Do you have type 2 diabetes?" and branching through the 5 questions above, ending with specific medication recommendations]

The framework eliminates 80% of the decision complexity. The remaining 20% is individual response variability, which you can't predict in advance. Some patients lose 25% of body weight on semaglutide. Others lose 8% on tirzepatide. The averages predict the most likely outcome, not the guaranteed outcome.

What's coming: the pipeline of next-generation GLP-1 medications

The GLP-1 space is moving toward triple agonists, oral formulations, and longer-acting versions.

Medications in phase 3 trials (expected FDA submission 2026-2027):

• Retatrutide (Eli Lilly): GLP-1/GIP/glucagon triple agonist. Phase 2 data showed 24.2% mean weight loss at 48 weeks, the highest efficacy of any obesity medication in clinical trials (Jastreboff et al., New England Journal of Medicine, 2023). Phase 3 trials ongoing.
• Survodutide (Boehringer Ingelheim): GLP-1/glucagon dual agonist. Phase 2 data showed 15.7% mean weight loss at 46 weeks. Phase 3 trials ongoing.
• Orforglipron (Eli Lilly): Oral GLP-1 receptor agonist, non-peptide small molecule. Phase 2 data showed 14.7% mean weight loss at 36 weeks. First oral GLP-1 that doesn't require fasting administration.
• CagriSema (Novo Nordisk): Fixed-ratio combination of semaglutide and cagrilintide (amylin analog). Phase 2 data showed 17.1% mean weight loss at 32 weeks.

Medications in phase 2 trials (expected FDA submission 2027-2028):

• Mazdutide (Hanmi Pharmaceutical): GLP-1/glucagon dual agonist
• BI 456906 (Boehringer Ingelheim): GLP-1/GIP/glucagon triple agonist
• AMG 133 (Amgen): GLP-1/GIP dual agonist plus antibody-based approach

The trend is clear: dual and triple agonists produce greater weight loss than single-agonist GLP-1s. The trade-off is side-effect burden. Glucagon agonism increases nausea and raises heart rate. Triple agonists in phase 2 trials have 40 to 50% nausea rates compared to 20 to 30% for semaglutide.

The other trend is oral formulations. Rybelsus proved oral GLP-1 delivery is possible, but the fasting requirement limits real-world adherence. Orforglipron is a different chemical class (non-peptide) that doesn't require fasting and produces weight loss comparable to injectable semaglutide. If phase 3 trials confirm phase 2 efficacy, oral GLP-1s may displace injectables for patients who refuse injections.

Prediction: By Q4 2027, at least one triple-agonist GLP-1 medication will receive FDA approval. Retatrutide is the most likely candidate based on trial timeline and Lilly's regulatory track record. The approval will shift the standard of care for obesity treatment from 15% mean weight loss (current semaglutide benchmark) to 20 to 24% mean weight loss.

When you should NOT use a GLP-1 medication

GLP-1 medications are not appropriate for every patient seeking weight loss. The contraindications and caution scenarios are:

Absolute contraindications (do not use):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or breastfeeding (no human safety data; animal studies show fetal harm)
• History of severe hypersensitivity reaction to the specific GLP-1 medication

Relative contraindications (use with caution or avoid):

• History of pancreatitis (GLP-1s increase pancreatitis risk from 0.1% to 0.3% in clinical trials)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Severe gastroparesis (GLP-1s worsen gastric emptying)
• History of suicidal ideation (semaglutide carries an FDA warning based on post-market reports, though causality is not established)
• Diabetic retinopathy (rapid glucose lowering can transiently worsen retinopathy; ophthalmology monitoring recommended)
• Renal impairment with eGFR under 30 (limited safety data; dose adjustment may be needed)

Clinical scenarios where GLP-1s are not first-line:

• BMI under 27 with no comorbidities (not FDA-approved; lifestyle modification is first-line)
• Active eating disorder (GLP-1-induced appetite suppression can worsen restrictive eating patterns)
• Inability to afford ongoing treatment (weight regain after discontinuation is common; starting a medication you can't sustain long-term creates a worse outcome than not starting)

The strongest argument against GLP-1 use is the durability question. Weight loss is maintained only while taking the medication. The STEP 1 extension trial showed that patients who discontinued semaglutide after 68 weeks regained two-thirds of lost weight within 52 weeks (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

This is not a medication failure. It's the expected pharmacology. GLP-1 medications treat obesity as a chronic disease requiring chronic treatment, the same way statins treat hyperlipidemia. The question is whether the patient is prepared for indefinite treatment. If not, the medication may not be the right choice.

FAQ

What is a GLP-1 medication? GLP-1 (glucagon-like peptide-1) medications are a class of drugs that mimic a natural hormone your intestines release after eating. They slow stomach emptying, reduce appetite, increase insulin secretion, and decrease glucagon release. Originally developed for type 2 diabetes, several are now FDA-approved for chronic weight management.

How many GLP-1 medications are FDA-approved? Eight GLP-1 receptor agonists have received FDA approval: exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide, albiglutide (discontinued), lixisenatide, and oral semaglutide. Three are approved specifically for weight loss: Saxenda (liraglutide 3.0 mg), Wegovy (semaglutide 2.4 mg), and Zepbound (tirzepatide 15 mg).

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is FDA-approved for chronic weight management at 2.4 mg weekly. The active ingredient and mechanism are identical. The difference is indication, approved dose, and insurance coverage rules.

What is the difference between Mounjaro and Zepbound? Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes at doses from 2.5 mg to 15 mg weekly. Zepbound is FDA-approved for chronic weight management at the same dose range. The medications are identical except for FDA indication and packaging.

Which GLP-1 medication causes the most weight loss? Tirzepatide (Zepbound, Mounjaro) produces the most weight loss in clinical trials: 20.9% mean total body weight loss at 72 weeks in the SURMOUNT-1 trial. Semaglutide 2.4 mg (Wegovy) is second at 14.9% mean weight loss. Liraglutide 3.0 mg (Saxenda) produces 8.0% mean weight loss.

Are compounded GLP-1 medications safe? Compounded semaglutide and tirzepatide from reputable pharmacies use the same active ingredient as brand-name products. The difference is manufacturing oversight: FDA batch testing for brand-name vs state board of pharmacy oversight for compounded. Quality varies by pharmacy. FormBlends works only with pharmacies that maintain USP 797 certification and third-party sterility testing.

Can I switch from one GLP-1 to another? Yes. Switching between GLP-1 medications is common, usually due to inadequate weight loss, side effects, or cost. When switching, start at the equivalent dose of the new medication rather than restarting at the lowest dose. Your provider can calculate dose equivalency based on published conversion tables.

How long do I need to take a GLP-1 medication? GLP-1 medications are intended for chronic use. Weight loss is maintained only while taking the medication. Clinical trials show that patients who discontinue treatment regain most of the lost weight within 12 months. Think of GLP-1 treatment the same way you think of blood pressure medication: ongoing treatment for a chronic condition.

Do GLP-1 medications work without diet and exercise? Yes, but the results are better with lifestyle modification. The STEP 1 trial of semaglutide included diet and exercise counseling and produced 14.9% mean weight loss. Real-world studies without structured lifestyle intervention show 10 to 12% mean weight loss. The medication works through appetite suppression regardless of behavior change, but behavior change amplifies the effect.

What happens if I miss a dose of my GLP-1 medication? For weekly medications (semaglutide, tirzepatide, dulaglutide), take the missed dose as soon as you remember if it's within 5 days of the scheduled dose. If more than 5 days have passed, skip the missed dose and resume your regular schedule. Do not double dose. For daily medications (liraglutide), take the missed dose within 12 hours or skip it.

Can I drink alcohol while taking a GLP-1 medication? Alcohol is not contraindicated with GLP-1 medications, but it can worsen nausea and increase the risk of hypoglycemia if you also take insulin or sulfonylureas. Moderate alcohol consumption (1 to 2 drinks) is generally well-tolerated. Heavy drinking is not recommended due to increased nausea and gastrointestinal side effects.

Why is there a shortage of Wegovy and Zepbound? Demand for GLP-1 weight-loss medications exceeded manufacturing capacity starting in 2022. Novo Nordisk and Eli Lilly have expanded production facilities, but the build-out takes 18 to 24 months. The FDA declared shortages for semaglutide in December 2022 and tirzepatide in December 2023. Both remain on the shortage list as of April 2026, though supply has improved compared to 2023-2024.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Nuhoho S et al. Network meta-analysis comparing the efficacy and safety of GLP-1 receptor agonists for weight management in adults with overweight or obesity. The Lancet. 2023.
5. Shi Q et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Obesity Reviews. 2024.
6. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2022.
7. Blonde L et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Postgraduate Medicine. 2023.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
9. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
11. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
12. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. JAMA. 2019.
13. FDA Drug Shortages Database. Semaglutide and Tirzepatide Current Shortage Status. Updated April 2026.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Byetta, Bydureon, Victoza, Saxenda, Trulicity, Adlyxin, Tanzeum, Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim, Sanofi, or GlaxoSmithKline.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ {"@type": "Question", "name": "What is a GLP-1 medication?", "acceptedAnswer": {"@type": "Answer", "text": "GLP-1 (glucagon-like peptide-1) medications are a class of drugs that mimic a natural hormone your intestines release after eating. They slow stomach emptying, reduce appetite, increase insulin secretion, and decrease glucagon release. Originally developed for type 2 diabetes, several are now FDA-approved for chronic weight management."}}, {"@type": "Question", "name": "How many GLP-1 medications are FDA-approved?", "acceptedAnswer": {"@type": "Answer", "text": "Eight GLP-1 receptor agonists have received FDA approval: exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide, albiglutide (discontinued), lixisenatide, and oral semaglutide. Three are approved specifically for weight loss: Saxenda (liraglutide 3.0 mg), Wegovy (semaglutide 2.4 mg), and Zepbound (tirzepatide 15 mg)."}}, {"@type": "Question", "name": "What is the difference between Ozempic and Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is FDA-approved for chronic weight management at 2.4 mg weekly. The active ingredient and mechanism are identical. The difference is indication, approved dose, and insurance coverage rules."}}, {"@type": "Question", "name": "What is the difference between Mounjaro and Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes at doses from 2.5 mg to 15 mg weekly. Zepbound is FDA-approved for chronic weight management at the same dose range. The medications are identical except for FDA indication and packaging."}}, {"@type": "Question", "name": "Which GLP-1 medication causes the most weight loss?", "acceptedAnswer": {"@type": "Answer", "text": "Tirzepatide (Zepbound, Mounjaro) produces the most weight loss in clinical trials: 20.9% mean total body weight loss at 72 weeks in the SURMOUNT-1 trial. Semaglutide 2.4 mg (Wegovy) is second at 14.9% mean weight loss. Liraglutide 3.0 mg (Saxenda) produces 8.0% mean weight loss."}}, {"@type": "Question", "name": "Are compounded GLP-1 medications safe?", "acceptedAnswer": {"@type": "Answer", "text": "Compounded semaglutide and tirzepatide from reputable pharmacies use the same active ingredient as brand-name products. The difference is manufacturing oversight: FDA batch testing for brand-name vs state board of pharmacy oversight for compounded. Quality varies by pharmacy. FormBlends works only with pharmacies that maintain USP 797 certification and third-party sterility testing."}}, {"@type": "Question", "name": "Can I switch from one GLP-1 to another?", "acceptedAnswer": {"@type": "Answer", "text": "Yes. Switching between GLP-1 medications is common, usually due to inadequate weight loss, side effects, or cost. When switching, start at the equivalent dose of the new medication rather than restarting at the lowest dose. Your provider can calculate dose equivalency based on published conversion tables."}}, {"@type": "Question", "name": "How long do I need to take a GLP-1 medication?", "acceptedAnswer": {"@type": "Answer", "text": "GLP-1 medications are intended for chronic use. Weight loss is maintained only while taking the medication. Clinical trials show that patients who discontinue treatment regain most of the lost weight within 12 months. Think of GLP-1 treatment the same way you think of blood pressure medication: ongoing treatment for a chronic condition."}}, {"@type": "Question", "name": "Do GLP-1 medications work without diet and exercise?", "acceptedAnswer": {"@type": "Answer", "text": "Yes, but the results are better with lifestyle modification. The STEP 1 trial of semaglutide included diet and exercise counseling and produced 14.9% mean weight loss. Real-world studies without structured lifestyle intervention show 10 to 12% mean weight loss. The medication works through appetite suppression regardless of behavior change, but behavior change amplifies the effect."}}, {"@type": "Question", "name": "What happens if I miss a dose of my GLP-1 medication?", "acceptedAnswer": {"@type": "Answer", "text": "For weekly medications (semaglutide, tirzepatide, dulaglutide), take the missed dose as soon as you remember if it's within 5 days of the scheduled dose. If more than 5 days have passed, skip the missed dose and resume your regular schedule. Do not double dose. For daily medications (liraglutide), take the missed dose within 12 hours or skip it."}}, {"@type": "Question", "name": "Can I drink alcohol while taking a GLP-1 medication?", "acceptedAnswer": {"@type": "Answer", "text": "Alcohol is not contraindicated with GLP-1 medications, but it can worsen nausea and increase the risk of hypoglycemia if you also take insulin or sulfonylureas. Moderate alcohol consumption (1 to 2 drinks) is generally well-tolerated. Heavy drinking is not recommended due to increased nausea and gastrointestinal side effects."}}, {"@type": "Question", "name": "Why is there a shortage of Wegovy and Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "Demand for GLP-1 weight-loss medications exceeded manufacturing capacity starting in 2022. Novo Nordisk and Eli Lilly have expanded production facilities, but the build-out takes 18 to 24 months. The FDA declared shortages for semaglutide in December 2022 and tirzepatide in December 2023. Both remain on the shortage list as of April 2026, though supply